Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)

Ophthalmologica

Volumn 237, Issue 4, 2017, Pages 185-222

  Schmidt Erfurth, Ursula ^a   Garcia Arumi, Jose ^b   Bandello, Francesco ^c   Berg, Karina ^d   Chakravarthy, Usha ^e   Gerendas, Bianca S ^a   Jonas, Jost ^f   Larsen, Michael ^g   Tadayoni, Ramin ^h   Loewenstein, Anat ⁱ  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h HÔPITAL LARIBOISIÈRE   (France)

ⁱ TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti VEGF therapy; Diabetic macular edema; Steroids

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; HEMOGLOBIN A1C; RANIBIZUMAB; STEROID; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR;

BEST CORRECTED VISUAL ACUITY; BLOOD RETINA BARRIER; BODY MASS; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EARLY INTERVENTION; ENDOCRINOLOGIST; EUROPEAN; FLUORESCENCE ANGIOGRAPHY; GANGLION CELL LAYER THICKNESS; GLAUCOMA; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRARETINAL MICROVASCULAR ABNORMALITY; LASER COAGULATION; LOW LEVEL LASER THERAPY; METABOLIC REGULATION; MICROANEURYSM; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NEW VESSEL ELSEWHERE; NEW VESSEL ON THE DISC; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOLOGIST; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROLIFERATIVE DIABETIC RETINOPATHY; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SIDE EFFECT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THROMBOEMBOLISM; TREATMENT DURATION; VISUAL ACUITY; COMPLICATION; DISEASE MANAGEMENT; EUROPE; MACULAR EDEMA; MEDICAL SOCIETY; PROCEDURES;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; EUROPE; HUMANS; LASER COAGULATION; MACULAR EDEMA; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 85018525253     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000458539     Document Type: Review

References (170)

1. Klein R, Klein BE, Moss SE, Davis MD, De Mets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-1474
2. Kylstra JA, Brown JC, Jaffe GJ, Cox TA, Gallemore R, Greven CM, Hall JG, Eifrig DE. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology 1999; 106: 2068-2073
3. Bresnick GH. Diabetic macular edema. A review. Ophthalmology 1986; 93: 989-997
4. Carpineto P, Mastropasqua R, Marchini G, Toto L, Di Nicola M, Di Antonio L. Reproducibility, and repeatability of foveal avascular zone measurements in healthy subjects by optical coherence tomography angiography. Br J Ophthalmol 2016; 100: 671-676
5. Hwang TS, Jia Y, Gao SS, Bailey ST, Lauer AK, Flaxel CJ, Wilson DJ, Huang D. Optical coherence tomography angiography features of diabetic retinopathy. Retina 2015; 35: 2371-2376
6. Hwang TS, Gao SS, Liu L, Lauer AK, Bailey ST, Flaxel CJ, Wilson DJ, Huang D, Jia Y. Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy. JAMA Ophthalmol 2016; 134: 367-373
7. Shahlaee A, Pefkianaki M, Hsu J, Ho AC. Measurement of foveal avascular zone dimensions, and its reliability in healthy eyes using optical coherence tomography angiography. Am J Ophthalmol 2016; 161: 50-55.e51
8. Takase N, Nozaki M, Kato A, Ozeki H, Yoshida M, Ogura Y. Enlargement of foveal avascular zone in diabetic eyes evaluated by en face optical coherence tomography angiography. Retina 2015; 35: 2377-2383
9. Bradley PD, Sim DA, Keane PA, Cardoso J, Agrawal R, Tufail A, Egan CA. The evaluation of diabetic macular ischemia using optical coherence tomography angiography. Invest Ophthalmol Vis Sci 2016; 57: 626-631
10. Couturier A, Mane V, Bonnin S, Erginay A, Massin P, Gaudric A, Tadayoni R. Capillary plexus anomalies in diabetic retinopathy on optical coherence tomography angiography. Retina 2015; 35: 2384-2391
11. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques, and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 1987; 94: 761-774
12. Chew EY, Murphy RP, Newsome DA, Fine SL. Parafoveal telangiectasis, and diabetic retinopathy. Arch Ophthalmol 1986; 104: 71-75
13. Bolz M, Lammer J, Deak G, Pollreisz A, Mitsch C, Scholda C, Kundi M, Schmidt-Erfurth U. SAVE: a grading protocol for clinically significant diabetic macular oedema based on optical coherence tomography, and fluorescein angiography. Br J Ophthalmol 2014; 98: 1612-1617
14. Kozak I, El-Emam SY, Cheng L, Bartsch DU, Chhablani J, Freeman WR, Arevalo JF. Fluorescein angiography versus optical coherence tomography-guided planning for macular laser photocoagulation in diabetic macular edema. Retina 2014; 34: 1600-1605
15. Wang H, Chhablani J, Freeman WR, Chan CK, Kozak I, Bartsch DU, Cheng L. Characterization of diabetic microaneurysms by simultaneous fluorescein angiography, and spectral-domain optical coherence tomography. Am J Ophthalmol 2012; 153: 861-867. e861
16. Hua R, Liu L, Wang X, Chen L. Imaging evidence of diabetic choroidopathy in vivo: angiographic pathoanatomy, and choroidal-enhanced depth imaging. PLoS One 2013; 8: e83494
17. Dmuchowska DA, Krasnicki P, Mariak Z. Can optical coherence tomography replace fluorescein angiography in detection of ischemic diabetic maculopathy? Graefes Arch Clin Exp Ophthalmol 2014; 252: 731-738
18. Wessel MM, Nair N, Aaker GD, Ehrlich JR, D?Amico DJ, Kiss S. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol 2012; 96: 694-698
19. Patel RD, Messner LV, Teitelbaum B, Michel KA, Hariprasad SM. Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal, and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol 2013; 155: 1038-1044.e1032
20. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mones J, Richard G, Bandello F. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014; 98: 1144-1167
21. Gerendas B, Simader C, Deak GG, Prager SG, Lammer J, Waldstein SM, Kundi M, Schmidt-Erfurth U. Morphological parameters relevant for visual, and anatomic outcomes during anti-VEGF therapy of diabetic macular edema in the RESTORE trial. Invest Ophthalmol Vis Sci 2014; 55: 1791-1791
22. Bolz M, Kriechbaum K, Simader C, Deak G, Lammer J, Treu C, Scholda C, Prunte C, Schmidt-Erfurth U. In vivo retinal morphology after grid laser treatment in diabetic macular edema. Ophthalmology 2010; 117: 538-544
23. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE, and RIDE. Ophthalmology 2012; 119: 789-801
24. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A. The RESTORE Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema. Ophthalmology 2011; 118: 615-625
25. Lang GE, Berta A, Eldem BM, Simader C, Sharp D, Holz FG, Sutter F, Gerstner O, Mitchell P. Two-year safety, and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120: 2004-2012
26. Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014; 121: 1045-1053
27. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL, 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e1035
28. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254
29. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203
30. Prunte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnicka J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016; 100: 787-795
31. Sun JK, Lin MM, Lammer J, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 2014; 132: 1309-1316
32. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity, and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2012; 250: 61-70
33. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009; 116: 914-920
34. Gerendas BS, Waldstein SM, Simader C, Deak G, Hajnajeeb B, Zhang L, Bogunovic H, Abramoff MD, Kundi M, Sonka M, Schmidt-Erfurth U. Three-dimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography, and correlation with the level of diabetic macular edema. Am J Ophthalmol 2014; 158: 1039-1048
35. Early Treatment Diabetic Retinopathy Study research group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806
36. Cheema HR, Al Habash A, Al-Askar E. Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema. Int J Ophthalmol 2014; 7: 251-255
37. Sophie R, Lu N, Campochiaro PA. Predictors of functional, and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 2015; 122: 1395-1401
38. Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 2011; 52: 2741-2748
39. Sun JK, Radwan S, Soliman AZ, Lammer J, Lin MM, Prager SG, Silva PS, Aiello LB, Aiello LP. Neural retinal disorganization as a robust marker of visual acuity in current, and resolved diabetic macular edema. Diabetes 2015; 64: 2560-2570
40. Yiu G, Manjunath V, Chiu SJ, Farsiu S, Mahmoud TH. Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthalmol 2014; 158: 745-751.e742
41. Bonnin S, Tadayoni R, Erginay A, Massin P, Dupas B. Correlation between ganglion cell layer thinning, and poor visual function after resolution of diabetic macular edema. Invest Ophthalmol Vis Sci 2015; 56: 978-982
42. Hwang DJ, Lee EJ, Lee SY, Park KH, Woo SJ. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles. Invest Ophthalmol Vis Sci 2014; 55: 4213-4219
43. Rayess N, Rahimy E, Ying G-s, Bagheri N, Ho AC, Regillo CD, Vander JF, Hsu J. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol 2015; 159: 85-91.e83
44. Pemp B, Deak G, Prager S, Mitsch C, Lammer J, Schmidinger G, Scholda C, Schmidt-Erfurth U, Bolz M. Distribution of intraretinal exudates in diabetic macular edema during anti-vascular endothelial growth factor therapy observed by spectral domain optical coherence tomography, and fundus photography. Retina 2014; 34: 2407-2415
45. Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE, and RISE phase III clinical trials. Ophthalmology 2015; 122: 779-786
46. Mylonas G, Bolz M, Kriechbaum K, Treu C, Deak G, Lammer J, Scholda C, Schmidt-Erfurth U. Retinal architecture recovery after grid photocoagulation in diabetic macular edema observed in vivo by spectral domain optical coherence tomography. Retina 2013; 33: 717-725
47. Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012; 119: 2312-2318
48. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, Jampol LM, Stone TW. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122: 375-381
49. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd: Ranibizumab, and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-1398
50. Gerendas BS, Prager SG, Deak GG, Waldstein SM, Lammer J, Simader C, Kundi M, Schmidt-Erfurth U. Morphological parameters relevant for long-term outcomes during therapy of diabetic macular edema in the RESTORE Extension trial. Invest Ophthalmol Vis Sci 2015; 56: 4686-4686
51. Xu X, Lee K, Zhang L, Sonka M, Abramoff M. Stratified sampling voxel classification for segmentation of intraretinal, and subretinal fluid in longitudinal clinical OCT data. IEEE Trans Med Imaging, Epub ahead of print
52. Schlegl T, Waldstein SM, Vogl WD, Schmidt-Erfurth U, Langs G. Predicting semantic descriptions from medical images with convolutional neural networks. Inf Process Med Imaging 2015; 24: 437-448
53. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic, and other retinal characteristics at baseline: ETDRS report No. 19. Arch Ophthalmol 1995; 113: 1144-1155
54. Network DRCR: A randomized trial comparing intravitreal triamcinolone acetonide, and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447-1459.e1410
55. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year followup of a randomized trial comparing focal/grid photocoagulation, and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251
56. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev 2012; 8: 274-284
57. Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011; 52: 4314-4323
58. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, Cunha-Vaz JG, Chong NV. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation, and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341-1344
59. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015; 314: 2137-2146
60. Cilley JC, Barfi K, Benson AB 3rd, Mulcahy MF. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007; 7: 739-749
61. Mould DR, Sweeney KR. The pharmacokinetics, and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10: 84-96
62. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-512
63. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor, and pigment epithelium-derived factor before, and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94: 1215-1218
64. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before, and after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib in patients with agerelated macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013; 97: 454-459
65. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: twoyear results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123: 1351-1359
66. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety, and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405
67. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614
68. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-1665
69. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE, and RIDE. Ophthalmology 2013; 120: 2013-2022
70. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258-1267
71. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013; 120: 2300-2309
72. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab, and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-andextend protocol. Ophthalmology 2015; 122: 146-152
73. Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab Versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane systematic review. Ophthalmology 2016; 123: 70-77.e71
74. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy, and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
75. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin, and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy, and tumors. J Biol Chem 1999; 274: 23463-23467
76. Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS. Outcomes with as-needed ranibizumab after initial monthly therapy: longterm outcomes of the phase III RIDE, and RISE Trials. Ophthalmology 2015; 122: 2504-2513.e2501
77. Chen G, Li W, Tzekov R, Jiang F, Mao S, Tong Y. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials. PLoS One 2014; 9: e115797
78. Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study. Ophthalmology 2015; 122: 1811-1819
79. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik JF. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA, and VIVID studies. Ophthalmology 2015; 122: 2044-2052
80. Tan CS, Li KZ, Lim TH. Calculating the predicted retinal thickness from spectral domain, and time domain optical coherence tomography-comparison of different methods. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1491-1499
81. Leal EC, Manivannan A, Hosoya K, Terasaki T, Cunha-Vaz J, Ambrosio AF, Forrester JV. Inducible nitric oxide synthase isoform is a key mediator of leukostasis, and blood-retinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci 2007; 48: 5257-5265
82. Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology, and treatment. Cell Biosci 2014; 4: 27
83. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30: 65-84
84. White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults, and adolescents. Diabetes 2010; 59: 1244-1253
85. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol 2003; 81: 1-44
86. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep 2012; 12: 364-375
87. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis, and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46: 1440-1444
88. Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, Nam DH. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686-694
89. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867
90. Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H. A randomized trial comparing intravitreal triamcinolone, and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina 2008; 28: 919-930
91. Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, Liu CC, Li XY, Hollander DA, Schiffman RM, Whitcup SM. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851
92. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914
93. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923
94. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics, and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52: 80-86
95. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, Oliver A, Rabinovitch T, Sheidow TG, Tourville E, Wittenberg LA, Sigouin C, Baptiste DC. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 2015; 9: 1255-1268
96. Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, Tolentino M, Gupta A, Duarte L, Madreperla S, Gonder J, Kapik B, Billman K, Kane FE. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011; 118: 626-635.e622
97. Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121: 1892-1903
98. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billman K, Kapik B, Green K, Kane F. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117: 1393-1399.e1393
99. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review, and metaanalysis. JAMA Ophthalmol 2016; 134: 21-29
100. Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment, and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 2001; 131: 44-49
101. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL. The role of the vitreous in diabetic macular edema. Ophthalmology 1988; 95: 1335-1339
102. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors, and concomitants. Acta Ophthalmol Scand 1999; 77: 170-175
103. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A. Association between the short-term natural history of diabetic macular edema, and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 1997; 104: 473-478
104. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis, and treatment. Surv Ophthalmol 2009; 54: 1-32
105. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before, and after vitrectomy for diabetic cystoid macular edema. Am J Ophthalmol 2000; 130: 740-744
106. Park JH, Woo SJ, Ha YJ, Yu HG. Effect of vitrectomy on macular microcirculation in patients with diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1009-1017
107. Sebag J, Balazs EA. Pathogenesis of cystoid macular edema: an anatomic consideration of vitreoretinal adhesions. Surv Ophthalmol 1984; 28(suppl): 493-498
108. Tamura K, Yokoyama T, Ebihara N, Murakami A. Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema. Jpn J Ophthalmol 2012; 56: 280-287
109. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction, and edema associated with posterior hyaloidal traction. Ophthalmology 1992; 99: 753-759
110. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178-186
111. Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema, and vitreomacular traction. Ophthalmology 2010; 117: 1087-1093.e1083
112. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina 2010; 30: 1488-1495
113. Bahadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with, and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol 2005; 26: 3-8
114. Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H, Takeuchi S. Early postoperative retinal thickness changes, and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 2003; 135: 14-19
115. Ikeda T, Sato K, Katano T, Hayashi Y. Improved visual acuity following pars plana vitrectomy for diabetic cystoid macular edema, and detached posterior hyaloid. Retina 2000; 20: 220-222
116. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004; 242: 630-637
117. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid, and the inner limiting membrane. Retina 2000; 20: 126-133
118. Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009; 29: 464-472
119. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001; 239: 264-270
120. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol 2002; 134: 214-219
121. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996; 122: 258-260
122. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 2007; 27: 557-566
123. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol 2005; 140: 295-301
124. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu AF. Pars plana vitrectomy, and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol 2006; 16: 573-581
125. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139: 795-801
126. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R. Comparative evaluation of vitrectomy, and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2007; 245: 360-368
127. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol 2005; 89: 81-86
128. Patel JI, Hykin PG, Schadt M, Luong V, Bunce C, Fitzke F, Gregor ZJ. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye (Lond) 2006; 20: 873-881
129. Doi N, Sakamoto T, Sonoda Y, Yasuda M, Yonemoto K, Arimura N, Uchino E, Ishibashi T. Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized pairedeyes. Graefes Arch Clin Exp Ophthalmol 2012; 250: 71-78
130. Kim YT, Kang SW, Kim SJ, Kim SM, Chung SE. Combination of vitrectomy, IVTA, and laser photocoagulation for diabetic macular edema unresponsive to prior treatments; 3-year results. Graefes Arch Clin Exp Ophthalmol 2012; 250: 679-684
131. Stefaniotou M, Aspiotis M, Kalogeropoulos C, Christodoulou A, Psylla M, Ioachim E, Alamanos I, Psilas K. Vitrectomy results for diffuse diabetic macular edema with, and without inner limiting membrane removal. Eur J Ophthalmol 2004; 14: 137-143
132. Hoerauf H, Bruggemann A, Muecke M, Luke J, Muller M, Stefansson E, Hammes HP, Weiss C. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol 2011; 249: 997-1008
133. Bardak Y, Cekic O, Tig SU. Comparison of ICG-assisted ILM peeling, and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema. Eye (Lond) 2006; 20: 1357-1359
134. Kumagai K, Hangai M, Ogino N, Larson E. Effect of internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema. Retina 2015; 35: 1422-1428
135. Figueroa MS, Contreras I, Noval S. Surgical, and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008; 28: 420-426
136. Shiba T, Kamura Y, Yagi F, Sato Y. Comparison of surgical procedures for vitreous surgery in diabetic macular edema. Jpn J Ophthalmol 2009; 53: 120-124
137. Shah SP, Patel M, Thomas D, Aldington S, Laidlaw DA. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study. Br J Ophthalmol 2006; 90: 33-36
138. Bonnin S, Sandali O, Bonnel S, Monin C, El Sanharawi M. Vitrectomy with internal limiting membrane peeling for tractional, and nontractional diabetic macular edema: Long-term Results of a Comparative Study. Retina 2015; 35: 921-928
139. Yamada Y, Suzuma K, Ryu M, Tsuiki E, Fujikawa A, Kitaoka T. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res 2013; 38: 1261-1265
140. Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1415-1420
141. Murakami T, Nishijima K, Akagi T, Uji A, Horii T, Ueda-Arakawa N, Muraoka Y, Yoshimura N. Segmentational analysis of retinal thickness after vitrectomy in diabetic macular edema. Invest Ophthalmol Vis Sci 2012; 53: 6668-6674
142. Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus, and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr 2013; 5: 57
143. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence, and mortality: facts, and fallacies. Nat Rev Endocrinol 2016; 12: 616-622
144. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014; 2: 56-64
145. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376: 124-136
146. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL 3rd, Knatterud GL. Risk factors for high-risk proliferative diabetic retinopathy, and severe visual loss: Early Treatment Diabetic Retinopathy Study Report 18. Invest Ophthalmol Vis Sci 1998; 39: 233-252
147. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control, and diabetic retinopathy. Curr Diabetes Rev 2009; 5: 3-7
148. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control, and Complications Trial. Diabetes Control, and Complications Trial Research Group. Ophthalmology 1995; 102: 647-661
149. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853
150. Retinopathy, and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control, and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group. N Engl J Med 2000; 342: 381-389
151. Zhang L, Krzentowski G, Albert A, Lefebvre PJ. Risk of developing retinopathy in Diabetes Control, and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24: 1275-1279
152. Writing Team for the Diabetes Control, and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569
153. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control, and Complications Trial. Arch Ophthalmol 2008; 126: 1707-1715
154. Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014: CD009122
155. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
156. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865
157. Keech AC, Mitchell P, Summanen PA, O?Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d?Emden MC, Crimet DC, O?Connell RL, Colman PG. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697
158. Early worsening of diabetic retinopathy in the Diabetes Control, and Complications Trial. Arch Ophthalmol 1998; 116: 874-886
159. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting glucose, and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008; 371: 736-743
160. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control, and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
161. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
162. Liew G, Mitchell P, Wong TY. Systemic management of diabetic retinopathy. BMJ 2009; 338: b441
163. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control, and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
164. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy, and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918
165. Cheung N, Wong TY. Fenofibrate, and diabetic retinopathy. Lancet 2008; 371: 721-722; author reply 722
166. Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 1981; 21: 1-226
167. Heng LZ, Pefianaki M, Hykin P, Patel PJ. Interobserver agreement in detecting spectraldomain optical coherence tomography features of diabetic macular edema. PLoS One 2015; 10: e0126557
168. Arevalo JF, Lasave AF, Arias JD, Serrano MA, Arevalo FA. Clinical applications of optical coherence tomography in the posteri-or pole: the 2011 Jose Manuel Espino Lecture-Part II. Clin Ophthalmol 2013; 7: 2181-2206
169. Lee J, Rosen R. Optical coherence tomography angiography in diabetes. Curr Diabetes Rep 2016; 16: 123
170. Lee J, Moon BG, Cho AR, Yoon YH. Optical coherence tomography angiography of DME, and its association with anti-VEGF treatment response. Ophthalmology 2016; 123: 2368-2375